This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BOSULIF®▼ (bosutinib) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BOSULIF Prescribing Information for Great Britain and for Northern Ireland, and adverse event reporting information can be found at the bottom of the page.

Bosulif dosing guide

For information on dosing and dose adjustments, view Dosing Guide

Download here

Recommended starting dose in FIRST-LINE1

400mg BOSULIF for adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)

Recommended starting dose in SECOND-LINE AND BEYOND1

500mg BOSULIF for adult patients with CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options

DOSE ADJUSTMENT1

100mg BOSULIF for dose escalation and reduction in increments between 300mg and 600mg (known as range of efficacy), depending on patient response and tolerability. Please refer to Summary of Product Characteristics for full guidance on when to escalate or reduce BOSULIF dosing by 100mg increments.

Colour and size of tablets shown are not representative of the actual tabelts and are for illustrative purposes only. 100 mg tablets width : 5.6 mm, length : 10.7 mm : 400 mg tablets width : 8.8 mm, length : 16.9 mm : 500 mg tablets widgth : 9.5 mm, lenth 18.3 mm. 1

Explore more

Perspectives in Managing CML

Hear views from the MDT: Rebecca Hallam (nurse) and Andrea Preston (pharmacist) with advice on how to support patients through their treatment

Learn More

New challenges: long-term TKI therapy

Hear Dr. Alex Lyon’s views on long-term TKI treatment in an ageing patient population video

Editable Link Text
Watch the video

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References:
  1. BOSULIF Summary of Product Characteristics for Great Britain click here. BOSULIF Summary of Product Characteristics for Northern Ireland click here.
PP-BOS-GBR-1306. September 2021
Quick Links

Take a look at the other resources to support you

Support and Resources

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No